Anti-SARS-CoV-2 NP monoclonal antibody (CABT-RM320)

Specifications


Host Species
Rabbit
Antibody Isotype
IgG
Clone
120
Species Reactivity
SARS-CoV-2, SARS-CoV
Conjugate
unconjugated

Applications


Application Notes
WB:1:1000-1:5000
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.

Target


Alternative Names
SARS-CoV-2 NP; SARS-CoV-2 Nucleoprotein; SARS-CoV-2; SARS-CoV; 2019-nCoV; Coronavirus

Citations


Have you cited CABT-RM320 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Detection of SARS-CoV-2 by bronchoscopy after negative testing: Stay vigilant for COVID-19

RESPIRATORY MEDICINE CASE REPORTS

Authors: Ramos, Kathleen J.; Kapnadak, Siddhartha G.; Collins, Bridget F.; Pottinger, Paul S.; Wall, Richard; Mays, James A.; Perchetti, Garrett A.; Jerome, Keith R.; Khot, Sandeep; Limaye, Ajit P.; Mathias, Patrick C.; Greninger, Alexander

Purpose: Real-time polymerase chain reaction (RT-PCR) detection of severe acute respiratory syndrome coronavirus (SARS-CoV-2) is required for diagnosis of coronavirus disease 2019 (COVID-19). Sensitivity of RT-PCR nasopharyngeal (NP) testing is presumed to be high, but there is no gold standard against which this has been determined. The objective was to determine whether lower respiratory tract infection (LRTI), detected in bronchoalveolar lavage fluid (BALF), occurs in the absence of upper respiratory tract infection with clinical testing of both specimen types. Methods: Between March 26, 2020 and April 17, 2020 at the University of Washington Medical Center all patients with BALF specimens clinically tested for SARS-CoV-2 were identified. We assessed the proportion of patients with positive RT-PCR for SARS-CoV-2 in BALF after negative NP testing. We describe 3 cases with positive testing in BALF. Results: Among 16 patients with BALF samples, 3 cases (19%) had SARS-CoV-2 detected in BALF. In Case 1, negative NP testing occurred early in the infection and respiratory symptoms may have been missed due to neurologic injury. In Case 2, outpatient diagnosis was aspiration pneumonia, but clinical suspicion remained high for COVID-19 at hospitalization based on epidemiological and clinical features. All 3 cases involved older adults (age >65 years), one of whom was immunosuppressed in the setting of lung transplantation (Case 3). Conclusions: These data demonstrate that SARS-CoV-2 LRTI occurs in the presence of negative NP testing. NP testing may underestimate the prevalence of COVID-19 and has implications for spread of SARS-CoV2 in the community and healthcare setting.

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

LANCET INFECTIOUS DISEASES

Authors: To, Kelvin Kai-Wang; Tsang, Owen Tak-Yin; Leung, Wai-Shing; Tam, Anthony Raymond; Wu, Tak-Chiu; Lung, David Christopher; Yip, Cyril Chik-Yan; Cai, Jian-Piao; Chan, Jacky Man-Chun; Chik, Thomas Shiu-Hong; Lau, Daphne Pui-Ling; Choi, Chris Yau-Chung; Chen, Lin-Lei; Chan, Wan-Mui; Chan, Kwok-Hung; Ip, Jonathan Daniel; Ng, Anthony Chin-Ki; Poon, Rosana Wing-Shan; Luo, Cui-Ting; Cheng, Vincent Chi-Chung; Chan, Jasper F. W.; Hung, Ivan Fan-Ngai; Chen, Zhiwei; Chen, Honglin; Yuen, Kwok-Yung

Background Coronavirus disease 2019 (COVID-19) causes severe community and nosocomial outbreaks. Comprehensive data for serial respiratory viral load and serum antibody responses from patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not yet available. Nasopharyngeal and throat swabs are usually obtained for serial viral load monitoring of respiratory infections but gathering these specimens can cause discomfort for patients and put health-care workers at risk. We aimed to ascertain the serial respiratory viral load of SARS-CoV-2 in posterior oropharyngeal (deep throat) saliva samples from patients with COVID-19, and serum antibody responses. Methods We did a cohort study at two hospitals in Hong Kong. We included patients with laboratory-confirmed COVID-19. We obtained samples of blood, urine, posterior oropharyngeal saliva, and rectal swabs. Serial viral load was ascertained by reverse transcriptase quantitative PCR (RT-qPCR). Antibody levels against the SARS-CoV-2 internal nucleoprotein (NP) and surface spike protein receptor binding domain (RBD) were measured using EIA. Whole-genome sequencing was done to identify possible mutations arising during infection. Findings Between Jan 22,2020, and Feb 12,2020,30 patients were screened for inclusion, of whom 23 were included (median age 62 years [range 37-75]). The median viral load in posterior oropharyngeal saliva or other respiratory specimens at presentation was 5.2 log 10 copies per mL (IQR 4.1-7.0). Salivary viral load was highest during the first week after symptom onset and subsequently declined with time (slope -0.15, 95% CI -0.19 to -0.11; R-2=0.71). In one patient, viral RNA was detected 25 days after symptom onset. Older age was correlated with higher viral load (Spearman's p=0.48,95% CI 0.074-0.75; p=0.020). For 16 patients with serum samples available 14 days or longer after symptom onset, rates of seropositivity were 94% for anti-NP IgG (n=15), 88% for anti-NP IgM (n=14), 100% for anti-RBD IgG (n=16), and 94% for anti-RBD IgM (n=15). Anti-SARS-CoV-2-NP or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralisation titre (R-2 >0.9). No genome mutations were detected on serial samples. Interpretation Posterior oropharyngeal saliva samples are a non-invasive specimen more acceptable to patients and health-care workers. Unlike severe acute respiratory syndrome, patients with COVID-19 had the highest viral load near presentation, which could account for the fast-spreading nature of this epidemic. This finding emphasises the importance of stringent infection control and early use of potent antiviral agents, alone or in combination, for high-risk individuals. Serological assay can complement RT-qPCR for diagnosis. Copyright (C) 2020 Elsevier Ltd. All rights reserved.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket